SELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial

On May 18, 2020 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, reported the formation of the Independent Data Monitoring Committee (DMC) for its pivotal Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line anti-leukemic therapy (CR2) (Press release, Sellas Life Sciences, MAY 18, 2020, View Source [SID1234558226]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The DMC is comprised of an independent group of medical, scientific and biostatistics experts and is responsible for reviewing and evaluating patient safety and efficacy data for the Company’s Phase 3 REGAL clinical trial. The DMC will review study data at regular intervals in order to ensure the safety of all patients enrolled in the study. The Committee will also monitor the quality and overall conduct and ensure the validity, scientific and clinical merits of the study, including each site’s compliance with the requirements specified in the study protocol. The DMC is charged with assessing such actions in light of an acceptable benefit/risk profile for GPS and will also make applicable recommendations regarding the clinical trial to SELLAS.

"Our REGAL clinical trial is the only Phase 3 study focused on remission prolongation through maintenance post-CR2 therapy, a significant and growing unmet medical need. As such, it is critically important to maintain the highest levels of integrity for this pivotal study. With the formation of the DMC, comprised of highly regarded and experienced physicians and biostatisticians who will confer with the respected physicians on the Steering Committee recently announced, we believe that we have brought together world class experts to monitor and guide this critical study which has the potential to extend the life of AML patients in CR2," said Angelos Stergiou, MD, ScD h.c., President & Chief Executive Officer of SELLAS. "Furthermore, the DMC will be able, at its sole discretion, to directly and independently liaise with the U.S. Food and Drug Administration (FDA) in order to discuss potential early unblinding and discontinuation of the study in case of reliable evidence of safety and clinically significant positive efficacy of GPS. We believe that this further strengthens the integrity and conduct of our REGAL study."

The Data Monitoring Committee currently consists of four members:

Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center and Chair of the REGAL Data Monitoring Committee
Thomas Fleming, Ph.D., Professor and former department chair of the University of Washington Department of Biostatistics, Member of the Fred Hutchinson Cancer Research Center, former Director of the Statistical Center for HIV/AIDS Prevention Trial Network, NIAID, Special Government Employee for the FDA, and for more than 25 years, a regular member of several FDA Advisory Committees
Miguel-Angel Perales, M.D., Chief, Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center (MSKCC)
Stephane de Botton, M.D., Head of the Hematology Department at the Gustave Roussy Cancer Campus in Paris, France
Dr. Moshe Talpaz, commented, "I look forward to working together with the other esteemed members of the Data Monitoring Committee on SELLAS’ important pivotal Phase 3 REGAL study. While significant progress has been made over the last few years in putting AML patients into a second remission, the survival benefit has not yet improved correspondingly. Because those patients are by definition in a remission, risk and benefit must be very carefully balanced and it is of great scientific interest to me to be a part of that process, as GPS may have the potential to prolong survival, as the Chair of the independent data monitoring committee for the study focused specifically on that patient population."

"It is a privilege to contribute to safeguarding the interests of study participants and to protecting the integrity of a trial of such importance in enhancing our understanding about the effects of interventions in AML patients in complete remission," added Dr. Fleming.

The Company previously reported initial data from the Phase 2a study of GPS in AML patients in CR2 at a median follow-up of 19.3 months, showing median overall survival (OS) in vaccine-treated patients of 16.3 months vs. 5.4 months in a patient cohort contemporaneously treated with best standard therapy (p = 0.0175). The final analysis, at a median follow-up of 30.8 months, showed a median OS of 21 months in the GPS-treated patient cohort. A second previous Phase 2 study of GPS in AML patients who achieved first complete remission (CR1) also met its primary endpoint with an OS rate at 3 years from first vaccination of 47%.

The REGAL study is an ongoing 1:1 randomized, open-label study comparing GPS monotherapy in the maintenance setting to investigators’ choice best available treatment in AML patients who have achieved hematologic complete remission, with or without thrombocytopenia (CR2/CR2p), after second-line antileukemic therapy and who are deemed ineligible for or unable to undergo allogeneic stem-cell transplantation. The primary endpoint is OS from the time of study entry. Secondary endpoints include leukemia-free survival, antigen-specific T-cell immune response dynamics, measurable residual disease by multigene array, and assessments of AML clonal evolution and inflammasome molecular signatures in the tumor microenvironment in bone marrow biopsy samples. The Company anticipates interim analysis for safety and futility in the fourth quarter of 2021.

bluebird bio Announces Pricing of Public Offering of Common Stock

On May 18, 2020 bluebird bio, Inc. (Nasdaq: BLUE) reported the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts (Press release, bluebird bio, MAY 18, 2020, View Source [SID1234558242]). In addition, bluebird bio has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock. All of the shares in the offering are to be sold by bluebird bio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC, BofA Securities and Cowen are acting as joint book-running managers of the offering. The offering is expected to close on or about May 21, 2020, subject to customary closing conditions.

bluebird bio anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $500 million, excluding any exercise of the underwriters’ option to purchase additional shares.

The shares are being offered by bluebird bio pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on May 18, 2020. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526, facsimile: (212) 902-9316, email: [email protected]; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or via email: [email protected]; and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

PANTHERx® Rare Pharmacy Selected by Deciphera Pharmaceuticals to Distribute QINLOCK™ (ripretinib), for Gastrointestinal Stromal Tumor (GIST) Patients

On May 18, 2020 PANTHERx Rare Pharmacy reported that it has been selected by Deciphera Pharmaceuticals as a limited distribution partner for new drug QINLOCK (ripretinib) (Press release, Deciphera Pharmaceuticals, MAY 18, 2020, View Source [SID1234558258]). QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib . Deciphera is focused on developing and commercializing innovative drugs that address the unmet medical needs of cancer patients by addressing key mechanisms of drug resistance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"PANTHERx is thrilled to be chosen by Deciphera Pharmaceuticals to deliver hope, this new oncology therapy with a novel mechanism of action, and our award winning white-glove services to patients living with advanced gastrointestinal stromal tumors," said Dr. Gordon Vanscoy, Chairman & CEO of PANTHERx. "As a partner, PANTHERx is proud to do our part in advancing oncology care and we are excited to offer more treatment options for people living with rare cancers."

QINLOCK (ripretinib) targets the broad spectrum of KIT and PDGFRα mutations known to drive GIST, including KIT mutations known to cause resistance to currently approved agents. Metastatic GIST is a disease characterized by many mutations, with over 90% of GIST patients harboring multiple mutations that drive progression of their disease. The complex heterogeneity of mutations within individual tumors and individual patients is a major cause of resistance to existing therapies.

While approved kinase inhibitors control certain initiating and drug resistance-causing mutations in KIT and PDGFRα, the kinases that drive disease progression in most GIST patients, these approved drugs fail to inhibit all known mutations. QINLOCK (ripretinib) was specifically designed to improve the treatment of GIST patients by inhibiting the full spectrum of known mutations in KIT and PDGFRα.

Learn more about the symptoms, diagnosis, and treatment of Gastrointestinal Stromal Tumors.

Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020

On May 18, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held June 22-24, 2020 (Press release, Seattle Genetics, MAY 18, 2020, View Source [SID1234558243]). Registration information to attend the virtual sessions can be found here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We will have a strong presence at the AACR (Free AACR Whitepaper) annual meeting with 12 data presentations highlighting our leadership in antibody-drug conjugate innovation and the depth and potential of our growing oncology pipeline of targeted therapies," said Scott Peterson, Ph.D., Senior Vice President of Research at Seattle Genetics. "Of key importance, a number of presentations will feature advances in our drug linker and payload components of ADCs. Building on our expertise in CD30 targeted therapies, data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas."

Dr. Peterson added, "In addition to our ADC technologies, we will also be presenting preclinical data highlighting the activity of our HER2 selective tyrosine kinase inhibitor tucatinib in preclinical models of HER2 mutant driven cancers and in the CNS setting. We look forward to sharing these presentations with the community at the second AACR (Free AACR Whitepaper) virtual meeting."

Abstracts can be found at www.aacr.org and include the following poster presentations below.

New ADC Technology Advances

Abstract Title: Novel Framework for Quantifying Synergy in High-Throughput Drug Combination Cytotoxicity Experiments (Abstract #835)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics

Abstract Title: Discovery of a Tripeptide-Based Camptothecin Drug-Linker for Antibody-Drug Conjugates with Potent Antitumor Activity and a Broad Therapeutic Window (Abstract #2885)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: Characterization of Payload Release from a Novel Camptothecin Drug-Linker (Abstract #2895)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Pipeline Programs

Abstract Title: SGN-CD30C, a New CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti-Tumor Activity and Superior Tolerability in Preclinical Studies (Abstract #2889)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: Utilizing PDX Models to Better Understand Factors that Predict Response to SGN-CD228A, an Antibody-Drug Conjugate (ADC) for Solid Tumors (Abstract #2888)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: SGN-B6A: A New MMAE ADC Targeting Integrin Beta-6 in Multiple Carcinoma Indications (Abstract #2906)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Antibody Drug Conjugates

Abstract Title: SEA-CD40 is a Non-Fucosylated Anti-CD40 Antibody with Potent Pharmacodynamic Activity in Preclinical Models and Patients with Advanced Solid Tumors (Abstract #5535)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Immune Response to Therapies 1

Commercial-Stage Programs

Abstract Title: Preclinical Characterization of Tucatinib in HER2-Amplified Xenograft and CNS Implanted Tumors (Abstract #1962)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Small Molecule Therapeutic Agents

Abstract Title: Tucatinib Inhibits Creatinine and Metformin Renal Tubule Secretion but has No Effect on Renal Function (GFR) (Abstract #3015)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib Inhibits CYP3A, CYP2C8 and P-gp-Mediated Elimination and is Impacted by CYP2C8 Inhibition in Healthy Volunteers (Abstract #3016)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib, a Selective Small Molecule HER2 Inhibitor, is Active in HER2 Mutant Driven Tumors (Abstract #4222)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Tyrosine Kinase and Phosphatase Inhibitors

Abstract Title: Enfortumab Vedotin, an Anti-Nectin-4 ADC Demonstrates Bystander Cell Killing and Immunogenic Cell Death Anti-Tumor Activity Mechanisms of Action in Urotherlial Cancers (Abstract #5581)
Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PT
Session: Immunotherapy

LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer

On May 18, 2020 LIPAC Oncology LLC reported the presentation of positive interim data from the TD-001 trial evaluating the safety and efficacy of investigational agent LiPax (paclitaxel) for intravesical instillation in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC) (Press release, Lipac Oncology, MAY 18, 2020, View Source [SID1234558259]). The study was accepted for presentation at the 2020 American Urological Association (AUA) Annual Meeting, published as a supplement to the April 2020 issue of The Journal of Urology and presented as part of the AUA Virtual Experience. The presentation can be accessed via the AUA website here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Trial results showed 100% (6/6) of patients treated with Transurethral Resection of Bladder Tumor (TURBT) and LiPax achieved a complete response three, six and nine months after the start of therapy. The 12-month recurrence free survival rate was 85% (5/6) and 100% (3/3) for all patients that reached the 18-month mark. Follow-up will continue until all patients have reached the 24-month mark.

"By pairing a simple outpatient procedure (TURBT) with LiPax, we have an opportunity to substantially improve both clinical outcomes and quality of life for people living with highly recurrent NMIBC," said Michael Oefelein, M.D., Chief Medical Officer of LIPAC Oncology. "This positive data validates that our proliposomal technology platform increases penetration and persistence of treatment and significantly improves the effectiveness of intravesical therapy."

Based on the biopsy results obtained from TURBT, NMIBC is stratified into three risk categories: low, intermediate, and high risk. To reduce recurrence and prevent progression, The AUA NMIBC guidelines recommend various durations of intravesical therapy after TURBT. The low to intermediate risk category is estimated to comprise 90,000 Americans, yet no intravesical agent is approved by the U.S. Food and Drug Administration for this disease.

In the study, LiPax was well tolerated with no change in patient reported urinary health related quality of life, no dose limiting toxicity (grade 3 or greater severity adverse events), and no evidence of systemic exposure to the active product ingredient (paclitaxel).

About The Phase 1/2a TD-001 Trial
TD-001 is an open-label, single-arm, multi-center Phase 1/2a clinical trial of TSD-001 (paclitaxel) for intravesical instillation to evaluate its safety and efficacy in patients with low to intermediate risk NMIBC.

About LiPax
LiPax (paclitaxel) for intravesical instillation is an investigational drug formulation of paclitaxel in Phase 2 development for the treatment of NMIBC. Utilizing the proliposomal technology platform, LIPAC Oncology’s proprietary formulation to enhance persistence and penetration of bladder tissue to paclitaxel, is designed to enhance the standard of care of outpatient endoscopic tumor removal, histological risk assessment followed by intravesical instillation using a standard urinary catheter. LIPAC Oncology completed enrollment in TD-001 in May 2020 and intends to advance the program to a pivotal study to further investigate LiPax in the treatment of this condition.